Tyler Van Buren
Stock Analyst at TD Cowen
(2.35)
# 2,541
Out of 5,114 analysts
59
Total ratings
43.75%
Success rate
1.11%
Average return
Main Sectors:
Stocks Rated by Tyler Van Buren
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| CCCC C4 Therapeutics | Initiates: Buy | n/a | $2.03 | - | 1 | Dec 2, 2025 | |
| BHVN Biohaven | Maintains: Buy | $50 → $15 | $10.85 | +38.25% | 3 | Nov 5, 2025 | |
| MBX MBX Biosciences | Initiates: Buy | n/a | $30.42 | - | 1 | Nov 4, 2025 | |
| TVTX Travere Therapeutics | Maintains: Buy | $30 → $40 | $34.51 | +15.91% | 2 | Oct 31, 2025 | |
| BBIO BridgeBio Pharma | Maintains: Buy | $60 → $95 | $76.30 | +24.51% | 2 | Oct 30, 2025 | |
| GILD Gilead Sciences | Maintains: Buy | $115 → $125 | $124.29 | +0.57% | 6 | Oct 23, 2025 | |
| IDYA IDEAYA Biosciences | Initiates: Buy | n/a | $33.55 | - | 1 | Jul 22, 2025 | |
| CGON CG Oncology | Initiates: Buy | n/a | $39.03 | - | 1 | Jan 7, 2025 | |
| KROS Keros Therapeutics | Downgrades: Hold | n/a | $20.26 | - | 2 | Dec 12, 2024 | |
| BCAX Bicara Therapeutics | Initiates: Buy | n/a | $17.60 | - | 1 | Oct 8, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | n/a | $31.84 | - | 1 | Sep 16, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Hold | $70 → $60 | $33.80 | +77.51% | 6 | Sep 13, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | n/a | $4.74 | - | 1 | Aug 13, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | n/a | $7.22 | - | 1 | Aug 6, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $1,030 → $1,200 | $767.96 | +56.26% | 7 | Jul 23, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | n/a | $19.56 | - | 1 | Jun 24, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | n/a | $35.11 | - | 1 | May 15, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Underperform | $30 | $55.86 | -46.29% | 2 | Dec 11, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Outperform | n/a | $33.40 | - | 1 | Nov 29, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Outperform | n/a | $63.96 | - | 1 | Oct 30, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Outperform | n/a | $78.54 | - | 1 | Aug 8, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Market Perform | n/a | $1.05 | - | 2 | Jan 6, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Outperform | $70 | $36.01 | +94.39% | 1 | Aug 8, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Outperform | n/a | $1.40 | - | 1 | Jul 12, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Outperform | n/a | $11.68 | - | 1 | Dec 7, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Outperform | n/a | $25.51 | - | 1 | Oct 11, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Overweight | $225 | $11.85 | +1,798.73% | 1 | Feb 10, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Overweight | $875 | $10.68 | +8,092.88% | 1 | Nov 10, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Overweight | $40 | $18.52 | +115.98% | 1 | Aug 18, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $35 → $30 | $18.79 | +59.66% | 3 | Aug 10, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Overweight | $50 | $1.23 | +3,965.04% | 1 | Jun 29, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Overweight | $30 | $3.44 | +772.09% | 1 | Apr 22, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Market Perform | n/a | $9.60 | - | 1 | Nov 2, 2017 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Market Perform | n/a | $30.35 | - | 1 | Aug 4, 2017 |
C4 Therapeutics
Dec 2, 2025
Initiates: Buy
Price Target: n/a
Current: $2.03
Upside: -
Biohaven
Nov 5, 2025
Maintains: Buy
Price Target: $50 → $15
Current: $10.85
Upside: +38.25%
MBX Biosciences
Nov 4, 2025
Initiates: Buy
Price Target: n/a
Current: $30.42
Upside: -
Travere Therapeutics
Oct 31, 2025
Maintains: Buy
Price Target: $30 → $40
Current: $34.51
Upside: +15.91%
BridgeBio Pharma
Oct 30, 2025
Maintains: Buy
Price Target: $60 → $95
Current: $76.30
Upside: +24.51%
Gilead Sciences
Oct 23, 2025
Maintains: Buy
Price Target: $115 → $125
Current: $124.29
Upside: +0.57%
IDEAYA Biosciences
Jul 22, 2025
Initiates: Buy
Price Target: n/a
Current: $33.55
Upside: -
CG Oncology
Jan 7, 2025
Initiates: Buy
Price Target: n/a
Current: $39.03
Upside: -
Keros Therapeutics
Dec 12, 2024
Downgrades: Hold
Price Target: n/a
Current: $20.26
Upside: -
Bicara Therapeutics
Oct 8, 2024
Initiates: Buy
Price Target: n/a
Current: $17.60
Upside: -
Sep 16, 2024
Initiates: Buy
Price Target: n/a
Current: $31.84
Upside: -
Sep 13, 2024
Maintains: Hold
Price Target: $70 → $60
Current: $33.80
Upside: +77.51%
Aug 13, 2024
Initiates: Buy
Price Target: n/a
Current: $4.74
Upside: -
Aug 6, 2024
Initiates: Buy
Price Target: n/a
Current: $7.22
Upside: -
Jul 23, 2024
Maintains: Buy
Price Target: $1,030 → $1,200
Current: $767.96
Upside: +56.26%
Jun 24, 2024
Initiates: Buy
Price Target: n/a
Current: $19.56
Upside: -
May 15, 2024
Initiates: Buy
Price Target: n/a
Current: $35.11
Upside: -
Dec 11, 2023
Downgrades: Underperform
Price Target: $30
Current: $55.86
Upside: -46.29%
Nov 29, 2023
Initiates: Outperform
Price Target: n/a
Current: $33.40
Upside: -
Oct 30, 2023
Initiates: Outperform
Price Target: n/a
Current: $63.96
Upside: -
Aug 8, 2023
Initiates: Outperform
Price Target: n/a
Current: $78.54
Upside: -
Jan 6, 2023
Downgrades: Market Perform
Price Target: n/a
Current: $1.05
Upside: -
Aug 8, 2022
Initiates: Outperform
Price Target: $70
Current: $36.01
Upside: +94.39%
Jul 12, 2022
Initiates: Outperform
Price Target: n/a
Current: $1.40
Upside: -
Dec 7, 2021
Initiates: Outperform
Price Target: n/a
Current: $11.68
Upside: -
Oct 11, 2021
Initiates: Outperform
Price Target: n/a
Current: $25.51
Upside: -
Feb 10, 2021
Initiates: Overweight
Price Target: $225
Current: $11.85
Upside: +1,798.73%
Nov 10, 2020
Initiates: Overweight
Price Target: $875
Current: $10.68
Upside: +8,092.88%
Aug 18, 2020
Initiates: Overweight
Price Target: $40
Current: $18.52
Upside: +115.98%
Aug 10, 2020
Maintains: Overweight
Price Target: $35 → $30
Current: $18.79
Upside: +59.66%
Jun 29, 2020
Initiates: Overweight
Price Target: $50
Current: $1.23
Upside: +3,965.04%
Apr 22, 2020
Initiates: Overweight
Price Target: $30
Current: $3.44
Upside: +772.09%
Nov 2, 2017
Downgrades: Market Perform
Price Target: n/a
Current: $9.60
Upside: -
Aug 4, 2017
Downgrades: Market Perform
Price Target: n/a
Current: $30.35
Upside: -